SimBioSys, Inc.
Computational platform integrating metabolomic, transcriptomic, and imaging data to construct spatial in silico models of cancer metabolism and cell-cell metabolite competition
- Sector
- Biotech
- Headquarters
- CHICAGO, IL
- Founded
- 2018
- Latest Form D
- $5.2M, Jan 2025
- Total capital
- $6.4M
- Federal grants
- $212K
- 1 award
- Rank in peer group#23 of 28
- Private capital raised
- $6.1M
- 2 Form D · last Jan 2025
- 22 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 10 pending · first 2020
- Rank in peer group#2 of 28
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$5.2M
- Private capital raisedForm D · SEC · 1st filing$900K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 28 peers
Line = medianBiotech · Software
- Federal grantsBelow median
- Granted patents#2 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Joseph PetersonResearcherExecutive Officer, DirectorLinked by $212K in grants as PI
- John A ColeExecutive OfficerNamed in SEC Form D filings
- Lucy CoassinDirectorNamed in SEC Form D filings
- Ronnie AndrewsDirectorNamed in SEC Form D filings
- Stacey StevensExecutive Officer, DirectorNamed in SEC Form D filings
- Vikram ChaudheryDirectorNamed in SEC Form D filings
Show all 7 people
- William HyunDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 12- PendingA Method For Cancer Prognostication Using Perfusion Kinetic Analysis Of Standard-of-care Dce MrisUSPTOApplication 18717324
- PendingThree-dimensional Modeling Of Patient-specific Tumors Using A Lattice Of Elastic-material PointsUSPTOApplication 17162643
- GrantedThree-dimensional Modeling Of Patient-specific Tumors Using A Lattice Of Elastic-material Points To Simulate Metabolism, Biochemical Reactions, Mechanical Forces, And Drug Interactions In A PatientUSPTOUS 10,943,701
Show all 12 patent records
- A Method For Cancer Prognostication Using Perfusion Kinetic Analysis Of Standard-of-care Dce MrisFeb 6, 2025 · Application 18717324Pending
- Three-dimensional Modeling Of Patient-specific Tumors Using A Lattice Of Elastic-material PointsJun 3, 2021 · Application 17162643Pending
- Three-dimensional Modeling Of Patient-specific Tumors Using A Lattice Of Elastic-material Points To Simulate Metabolism, Biochemical Reactions, Mechanical Forces, And Drug Interactions In A PatientMar 9, 2021 · US 10,943,701Granted
- Three-dimensional Modeling Of Patient-specific Tumors Using A Lattice Of Elastic-material Points To Simulate Metabolism Biochemical Reactions, Mechanical Forces And Drug Interactions In A PatientNov 17, 2020 · US 10,839,963Granted
- Metabolic Modeling For Disease Prognosis And TreatmentApplication PCTUS2022046520Pending
- Multi-tissue Segmentation And Deformation For Breast Cancer SurgeryApplication 19136095Pending
- Metabolic Modeling for Disease Prognosis and TreatmentApplication 63275085Pending
- Three-dimensional Modeling Of Patient-specific TumorsApplication PCTUS2019055724Pending
- Method for Cancer Prognostication Using Perfusion Kinetic Analysis of Standard-of-Care DCE MRIsApplication 63286194Pending
- Multi-tissue Segmentation And Deformation For Breast Cancer SurgeryApplication PCTUS2023078457Pending
- Multi-Tissue, 3D Simulation, and Visualization Systems for Breast Cancer Surgery PlanningApplication 63430645Pending
- A Method For Cancer Prognostication Using Perfusion Kinetic Analysis Of Standard-of-care Dce MrisApplication PCTUS2022052053Pending
Related companies, and why
- Dovetail Genomics, LLCSimilar federal contract value in Biotech · null in contracts
- RUBY BIO INCSimilar federal contract value in Biotech · null in contracts
- VasaMetrixSimilar federal contract value in Biotech · null in contracts
- C4 TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ASTROCYTE PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- Soteria Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .